Contract Biomanufacturing: Animal-Free, Protein-Based Biosimilars

Ventria Bioscience is an ideal partner for developing your protein-based, follow-on biologic. Our process development expertise and high-yield manufacturing platform have helped global pharmaceutical companies produce the following:

1. Recombinant enzymes, proteins, small peptides, multi-subunit molecules, monoclonal antibodies, and fusion proteins free of animal-derived components.
2. Proteins synthesized in a eukaryotic expression system, with dramatically higher yields compared to mammalian cell culture or alternative plant-based systems.
3. Fully processed products ready for preclinical testing, bioequivalence studies, and clinical testing.

Ventria Bioscience is already working with some of the biggest names in the global pharmaceutical industry to bring cost-effective biosimilars to market – including a recent deal to manufacture a life-sustaining enzyme replacement biosimilar with potential market size of $1 billion.

This email address is being protected from spambots. You need JavaScript enabled to view it. to learn more about how Ventria Bioscience can help with your next biosimilar development project.